OncoSil Medical Ltd (ASX:OSL) continues to make progress, having recruited 28 subjects into the study group of its Global Pancreatic Cancer Clinical Study Program, up from 23 patients on 22 September.
The company’s lead product, OncoSil™, is a targeted radioactive isotope, implanted directly into a patient’s pancreatic tumours via an endoscopic ultrasound.
Treatment with OncoSil is intended to deliver more concentrated and localised beta radiation compared to external beam radiation.
14 subjects in the study group have now been successfully implanted with the OncoSil device.
The company had earlier reported positive interim data relating to tumour response and disease control from the subjects implanted during the current phase of the program.
Importantly, study investigators have been encouraged by the clinical data that have emerged so far from the study.
Oncosil will share a study progress update at the European Association of Nuclear Medicine in Vienna on 21 October.
The European Association of Nuclear Medicine is the largest organisation dedicated to Nuclear Medicine in Europe.
It is worth noting that the prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is circa 5%.
The estimated world-wide market opportunity for OncoSil in pancreatic cancer exceeds $1 billion.